Partnership value grows 16% year-over-year, while clinical activity jumps 50%. A sampling of recent reports shows just how much immuno-oncology continues to grow. Behind the sunny forecasts is the expectation of numerous new treatments reaching market, following a significant increase in clinical activity. It is necessary to sustain the momentum generated by biopharmas through their immuno-oncology collaborations . . .